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A major discovery of recent decades has been the existence of
stem cells and their potential to repair many, if not most, tissues.
With the aging population, many attempts have been made to use
exogenous stem cells to promote tissue repair, so far with limited
success. An alternative approach, which may be more effective
and far less costly, is to promote tissue regeneration by targeting
endogenous stem cells. However, ways of enhancing endogenous
stem cell function remain poorly defined. Injury leads to the
release of danger signals which are known to modulate the
immune response, but their role in stem cell-mediated repair in
vivo remains to be clarified. Here we show that high mobility
group box 1 (HMGB1) is released following fracture in both hu-
mans and mice, forms a heterocomplex with CXCL12, and acts via
CXCR4 to accelerate skeletal, hematopoietic, and muscle regener-
ation in vivo. Pretreatment with HMGB1 2 wk before injury also
accelerated tissue regeneration, indicating an acquired prorege-
nerative signature. HMGB1 led to sustained increase in cell cycling
in vivo, and using Hmgb1−/− mice we identified the underlying mech-
anism as the transition ofmultiple quiescent stem cells fromG0 to GAlert.
HMGB1 also transitions human stem and progenitor cells to GAlert.
Therefore, exogenous HMGB1 may benefit patients in many clinical
scenarios, including trauma, chemotherapy, and elective surgery.
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Adult stem cells are an essential component of tissue ho-meostasis with indispensable roles in both physiological tis-
sue renewal and tissue repair following injury (1). The regenerative
potential of stem cells has been very successful for hematological
disorders (2). In contrast, there has been comparatively little clinical
impact on enhancing the regeneration of solid organs despite con-
tinuing major scientific and public interest (3). Strategies that rely on
ex vivo expansion of autologous stem cells on an individual patient
basis are prohibitively expensive (4), and success in animal models has
often failed to translate in late-phase clinical trials. The use of allo-
geneic cells would overcome the problems of limited supply but com-
monly entails risky lifelong immunosuppressive therapy. Some safety
concerns remain about induced pluripotent stem cells (5). Furthermore,
successful engraftment of exogenous stem cells to sites of tissue injury
requires a supportive inductive niche, and the typical proinflammatory
scarred bed in damaged recipient tissues is suboptimal (6).
An attractive alternative strategy, which overcomes many of the
limitations described above, is to promote repair by harnessing the
regenerative potential of endogenous stem cells (5, 7). This requires
identification of key soluble mediators that enhance the activity of
stem cells and can be administered systemically (8). An interesting
observation was made in 1970 that a priming injury at a distant site at
the time of or before the second trauma resulted in accelerated
healing (9, 10). This phenomenon was explained only recently, when
it was shown that a soluble mediator is released following the priming
tissue injury which transitions stem cells in the contralateral limb to a
state the authors termed “GAlert” (11), which is intermediate
between G0 and G1. In the presence of activating factors the
primed GAlert cells enter the cell cycle more rapidly than quies-
cent stem cells, leading to accelerated tissue repair (11). How-
ever, the identity of the soluble mediator(s) that transition stem
cells to GAlert remain to be clarified.
Our long-standing interest in tissue injury (12–14) has recently
centered on alarmins, a group of evolutionarily unrelated endogenous
molecules with diverse homeostatic intracellular roles, which, when
released from dying, injured, or activated cells, trigger an immune/
inflammatory response (15). Much effort has been focused on their
deleterious role in autoimmune and inflammatory conditions (15–19),
and of the few studies (15, 20) that have investigated their role in
tissue repair, none has used a combination of human tissues and
multiple animal-injury models to characterize their effects on precise
flow cytometry-defined endogenous adult stem cells in vivo. Here we
show that high mobility group box 1 (HMGB1) is a key upstream
mediator of tissue regeneration which acts by transitioning CXCR4+
skeletal, hematopoietic, and muscle stem cells from G0 to GAlert and
that, in the presence of appropriate activating factors, exogenous
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administration before or at the time of injury leads to accelerated
tissue repair.
Results
Alarmins Are Elevated Postinjury in Humans and Mice. Fracture
healing is a good model of tissue regeneration (21), and based on
our studies of the early events in fracture healing (13), including
the key role of neutrophils (14), we postulated that the alarmins
HMGB1 and S100A8/A9 may play key roles in tissue regeneration.
HMGB1 is a highly conserved, ubiquitous, and abundant non-
histone nuclear architectural protein that forms part of the tran-
scription machinery (18). S100A8/A9 proteins are calcium-binding
proteins that make up 40% of neutrophil cytoplasmic content (22).
Both these alarmins have been associated with regulating skeletal
cells (15, 23). We found elevated levels of HMGB1 and S100A8/
A9 in the circulation following fracture in both human patients and
mice (Fig. 1 A and B and Fig. S1 A and B).
HMGB1 Primes Human Mesenchymal Stem Cells for Osteogenic
Differentiation. We screened for the regenerative potential of
these alarmins in humans by assessing the osteogenic differen-
tiation of primary human mesenchymal stromal/stem cells (hMSCs)
(Fig. 1C and Fig. S2). We tested different redox forms of
HMGB1 because they are known to have contrasting effects (24).
Fully reduced (FR) all-thiol HMGB1 promotes chemotaxis (24),
whereas partially oxidized HMGB1 with a disulfide bond (DS) in-
duces TNF production (Figs. S1C and S2A) (24). To confirm that
the effect of FR-HMGB1 is due to its reduced state, we also used a
recombinant nonoxidizable all-serine form (3S) of HMGB1 (24).
Direct addition of alarmins to hMSCs did not promote osteogenic
differentiation (Fig. S2B), while DS-HMGB1, S100A8, and
S100A9 all inhibited this process in the presence of monocytes
(Fig. S2C), as did the supernatants from alarmin-treated mono-
cytes (Fig. S2D). Since alarmins are released before resident stem
cells are exposed to most osteogenic signals in vivo, we modeled
this temporal sequence in vitro and found that pre-exposure to
only FR-HMGB1 or 3S-HMGB1, but not the proinflammatory DS-
HMGB1, promoted osteogenic differentiation (Fig. 1 E and F and
Fig. S2E). We confirmed that in vivo administration of FR-
HMGB1 or 3S-HMGB1 did not lead to the production of TNF, IL-6,
or compensatory IL-10, in contrast to DS-HMGB1 (Fig. S3 I–K).
These data suggest that only FR-HMGB1 and 3S-HMGB1, which
cannot be oxidized, do not induce proinflammatory cytokine pro-
duction in vitro (Figs. S1C and S2A) or in vivo (Fig. S3 I–K), are viable
candidates to promote fracture healing, if administered before the
presence of potent osteogenic mediators.
Exogenous HMGB1 Accelerates Fracture Healing While Genetic
Deletion of HMGB1 Delays Fracture Healing. We optimized a mu-
rine fracture model (25) to permit longitudinal in vivo analysis
over time (Fig. S3 A–G and Movies S1 and S2) and found that
FR- or 3S-HMGB1 administered locally at the time of injury
accelerated fracture repair as evidenced by in vivo micro-computed
tomography (microCT) and mechanical strength testing (Fig. 2 A and
B), with a clear dose response (Fig. S3H). To evaluate the contri-
bution of endogenous HMGB1 to fracture healing, inducible whole-
bodyHmgb1−/−mice were generated (Fig. S4), as FR-HMGB1 in the
fracture microenvironment would originate frommultiple injured and
activated cell types, and constitutive deletion of HMGB1 is perina-
tally lethal (26). Fracture healing was dramatically impaired in these
animals as shown by reduced callus volume, callus bone mineral
density (BMD), and mechanical strength (Fig. 2C and Fig. S5A).
Thus, both exogenous and endogenous HMGB1 modulate the rate
of fracture healing.
HMGB1 Accelerates Fracture Healing via CXCL12 and CXCR4. Sub-
sequently, we sought to delineate the signaling pathways through
which HMGB1 promotes regeneration. FR-HMGB1 is known to
form a heterocomplex with CXCL12 (24, 27), a chemokine,
which in turn binds to the receptor CXCR4 (24, 27). We found
elevated plasma levels of the HMGB1–CXCL12 heterocomplex
in both human patients and mice following fracture injury (Fig. 2
D and E and Fig. S5B). Glycyrrhizin is the only known inhibitor
of the HMGB1–CXCL12 heterocomplex (27). It interacts with
the binding sites of HMGB1 for CXCL12 but not those for
RAGE on the Box regions of HMGB1 (27–29), thereby inhib-
iting the chemotactic activity of the heterocomplex in vitro and in
vivo (27, 28). Local administration of glycyrrhizin at the fracture
site inhibited the formation of the HMGB1–CXCL12 hetero-
complex (Fig. 2E) and resulted in delayed fracture healing (Fig.
2F and Fig. S5C), confirming that endogenous extracellular
HMGB1 modulates the rate of regeneration by forming a het-
erocomplex with CXCL12. We showed that murine skeletal stem
cells (mSSC) (30) express functional CXCR4 (Fig. 3 and Fig.
S5E) and that administration of AMD3100, a specific and clin-
ically approved small-molecule inhibitor of CXCR4, led to im-
paired fracture healing in wild-type mice (Fig. 2G and Fig. S5D)
and completely abolished the effects of exogenous HMGB1 (Fig.
2G and Fig. S5D). These data confirm that exogenous HMGB1
accelerates tissue regeneration through CXCR4, as was also recently
noted (20). The HMGB1–CXCL12 heterocomplex causes a confor-
mational change in CXCR4, which differs from that seen with
CXCL12 alone and thereby enhances chemotaxis compared with
CXCL12 (27). It was possible that the proregenerative effects of
HMGB1 were simply due to enhanced CXCL12-mediated chemo-
taxis. To test this, we administered exogenous CXCL12 alone, and
while we confirmed enhanced migration of cells to the fracture site
(Fig. S3L), we found only abnormal regeneration as evidenced by a
larger fracture callus without a concomitant increase in BMD or,
importantly, mechanical strength (Fig. 2 A and B). Therefore, the
improved regenerative effects of FR- or 3S-HMGB1 could not have
been due to enhanced CXCL12-mediated cell migration alone.
Taken together, these data show that, while the CXCL12–
CXCR4 axis is necessary for HMGB1-mediated accelerated tissue
regeneration, exogenous CXCL12 alone is insufficient to accelerate
fracture healing. This suggests that the HMGB1–CXCL12 hetero-
complex accelerates regeneration via an as yet unknown mechanism
rather than by enhanced chemotaxis alone.
Exogenous HMGB1 Led to a Sustained Increase in mSSC Cell Cycling in
Vivo. Apart from regulating chemotaxis, the CXCL12–
CXCR4 axis also influences the cycling of hematopoietic stem
cells (HSCs) by enforcing quiescence (31–36). Therefore, we in-
vestigated whether the HMGB1–CXCL12–CXCR4 axis addi-
tionally affects the cell cycle of stem cells to promote tissue
regeneration. We analyzed the propensity to cycle of mSSCs from
the fractured bones of mice that had been pulse-labeled with
BrdU (Fig. 4A). mSSCs from vehicle-treated animals displayed an
increasing propensity to cycle over time, which correlates with the
rising levels after fracture of osteogenic mediators (21, 37) in-
cluding bone morphogenetic proteins (BMPs) (30). Predictably,
exogenous administration of BMP2, a known activator of mSSCs
(30), resulted in an immediate increased propensity to cycle that
plateaued at day 2 at levels equivalent to those of vehicle-treated
controls at day 5. In comparison, mSSCs from animals treated
locally with exogenous FR- or 3S-HMGB1 showed an initial in-
crease intermediate between BMP2- and vehicle-treated controls
and beyond day 2 exhibited a higher rate of cycling than cells from
BMP2- or vehicle-treated animals. These data suggest that
HMGB1 has an effect markedly different from that of an activator
such as BMP2. Cells that have been preexposed to HMGB1 dis-
play an increased propensity to cycle when subsequently exposed
to endogenous activating signals released at the fracture site, in-
dicative of a lasting cellular effect that favors cell-cycle entry.
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Fig. 1. Alarmins are elevated postinjury in humans and mice, and HMGB1 primes human MSCs for osteogenic differentiation. (A and B) Elevated plasma
levels of S100A8/A9 and HMGB1 post femoral fracture in patients (A) and mice (B) collected within 4 h and at 3 h postfracture, respectively (n = 15 fractured
and 15 unfractured human patients; n = 6 unfractured and 4 fractured mice). (C) Heat map showing the results of an in vitro osteogenesis screen of alarmins
using hMSCs and monocytes. Green: elevated; red: reduced; black: unchanged; color brightness indicates dose trend. All data are shown and quantified in Fig.
S2. (D–F) Osteogenic differentiation is unchanged in hMSCs primed with S100A8 (D) but is increased when primed with FR- (E) or 3S-HMGB1 (F), as measured
by alkaline phosphatase (ALP) activity (n = 3 hMSC and 3 monocyte donors for each condition; similar results were obtained in three independent experi-
ments; significance is versus osteogenic medium control). DM, maintenance medium; OM, osteogenic medium; RPMI, Roswell Park Memorial Institute me-
dium. *P < 0.05, **P < 0.01, ****P < 0.0001.
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HMGB1 Transitions Multiple Human and Murine Stem and Progenitor
Cells to GAlert. An elegant series of experiments recently demon-
strated that systemic mediator(s) can transition stem cells distant
from the site of initial injury to a dynamic state of the cell cycle,
intermediate between G0 and G1, termed “GAlert” (11). In con-
trast to deeply quiescent G0 stem cells, GAlert cells are more
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Fig. 2. HMGB1 accelerates fracture healing via CXCL12–CXCR4. (A and B) Local addition of FR- or 3S-HMGB1 accelerates fracture healing, compared with
CXCL12 or vehicle controls, as shown by in vivo microCT radiographs (A) and analysis of callus volume, callus BMD, and day 28 mechanical strength (B) (n =
10 mice for each condition). (C) Hmgb1−/− mice have markedly delayed fracture healing compared with Hmgb1fl/fl control mice as shown by reduced callus
volume, callus BMD, and day 28 mechanical strength (n = 7 Hmgb1−/−mice, 8 Hmgb1fl/fl mice). (D and E) Elevated plasma levels of HMGB1–CXCL12 heterocomplex
postfracture in patients (D) and mice (E) collected within 4 h and at 3 h postfracture, respectively, and inhibition of HMGB1–CXCL12 heterocomplex formation with
glycyrrhizin treatment (n = 15 fractured and 15 unfractured human patients and n = 6 unfractured and 4 fracturedmice). (F and G) Glycyrrhizin delays fracture healing
compared with vehicle controls (F), and AMD3100 abrogates the effects of exogenous FR- or 3S-HMGB1 (G) as shown by callus volume, callus BMD, and day
28 mechanical strength (n = 10 mice for each condition). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant.
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metabolically active, as evidenced by increased cellular levels of
ATP, and are poised to enter the cell cycle when exposed to
activating signals. As HMGB1 enhanced the in vivo cycling of
mSSCs exposed to secondary activating signals, together with the
elevated systemic levels of HMGB1 andHMGB1-CXCL12 postinjury
in humans and mice, and our observations of accelerated fracture
healing with exogenous HMGB1 treatment, we hypothesized that
HMGB1 may in part accelerate fracture healing by transitioning
mSSCs to the recently defined GAlert state. We also postulated that
these effects may pertain to other previously well-identified and
characterized stem cells known to express CXCR4, including murine
hematopoietic stem cells (mHSCs) (31–36) and murine muscle stem
cells (mMuSCs) (Fig. S6B) (38).
The essential criteria describing the GAlert state are increased
ATP levels, mitochondrial DNA, cell size, faster entry to cell
cycle, and mTORC1 dependency (11). We found that the clini-
cally approved mTORC1 inhibitor rapamycin abolished the
accelerated healing effects of exogenous HMGB1 (Fig. 4B and
Fig. S6A). To investigate the other aspects of the GAlert state, we
compared the cells contralateral to a fracture injury (fracture
alerted) with those from mice injected i.v. with HMGB1 or ve-
hicle control. The severity of injury is important, as only sub-
stantial injuries, such as fractures, can transition stem cells to
GAlert, whereas simple venipuncture is insufficient (11). We ob-
served that not only mSSCs but also mHSCs and mMuSCs from
uninjured mice injected systemically with HMGB1 showed in-
creased ATP levels, mitochondrial DNA, and cell size compared
with vehicle-treated controls, and these levels were equivalent to
those in fracture-alerted stem cells (Fig. 4 D–F). In contrast,
stem cells from fractured Hmgb1−/− mice (Fig. 4C) and skeletal
stem cells (SSCs) from uninjured wild-type animals treated with
CXCL12 did not transition to GAlert (Fig. S6G). The essential
role of exogenous HMGB1 was further confirmed by a single
systemic dose of HMGB1 rescuing the elevated ATP GAlert
phenotype in stem cells from Hmgb1−/− mice (Fig. S6F). The
translational potential of our data is highlighted by the finding
that HMGB1-treated human CD34+ hematopoietic stem and
progenitor cells (hHSPCs) as well as hMSCs exhibited in-
creased ATP levels and mitochondrial DNA upon exposure to
HMGB1 but substantially less so than IFN-γ–(39) or BMP2-
activated cells (Fig. S6 C and D). To assess the rate of entry
into cell cycle in vivo, high-dose BrdU was continuously adminis-
tered, thus utilizing the dual properties of BrdU to label cells that
cycle while also acting as an injury signal that activates quiescent stem
cells and recruits them into the cell cycle (40). We found that the
mSSCs, mHSCs, and mMuSCs in HMGB1-treated mice entered the
cell cycle faster with continuous high-dose BrdU than in vehicle-
treated controls but much more slowly than activated stem cells
from the injured proximal hind limb of fractured animals (fracture
activated) (Fig. 4G). The previous genetic studies which demonstrated
the necessity of cMet signaling for mMuSCs to transition to GAlert
(11) recently led to the identification of HGF-A, an enzyme which
activates HGF, a ligand for c-Met, as a stem cell alerting factor (41).
Consistent with the cMet genetic studies (11), we found that in vivo
cMet inhibition with PHA 665752 or anti-cMet resulted in a sub-
stantially reduced expression of surface CXCR4 on mMuSCs (Fig.
S6E). Therefore, it is possible that the cMet and CXCR4 pathways
are complementary. Collectively, our data show that HMGB1
transitions multiple stem cells to GAlert, priming them to cycle
quickly in response to activation signals.
HMGB1 Accelerates Healing of Multiple Tissues, Even if Administered
2 Wk Before Injury. We hypothesized that HMGB1 would also
lead to accelerated tissue regeneration in other tissues where
stem cells could transition to GAlert, for example blood and
muscle. In mice myeloablated with a common chemotherapeutic
agent, 5-fluouracil (5-FU) (Fig. 5A), a single i.v. dose of
HMGB1 at the time of injury led to accelerated recovery of
systemic leukocyte (Fig. 5B) and neutrophil (Fig. 5C) counts.
This has significant translational relevance because the duration
of leucopenia and neutropenia is directly related to the risk of
infection, with each day of neutropenia approximately doubling
the risk of a febrile neutropenic episode (42). Febrile neu-
tropenia is a medical emergency with a mortality rate of 6.8–
9.5% (43), so accelerating hematopoietic recovery following
chemotherapy would make chemotherapy safer for patients. We
also found that local administration of a single dose of HMGB1 at
the time of injury resulted in accelerated muscle regeneration
following BaCl2 chemical injury (Fig. 5 D–F) (11). Our finding that
HMGB1 resulted in mSSCs having an increased propensity to
cycle that is sustained for several days (Fig. 4A) is consistent with
the previous observation that, following injury, stem cells in the
A
B
Fig. 3. mSSCs express functional surface CXCR4. (A and B) mSSCs express surface CXCR4 as shown by the FACS histogram plot (n = 4 mice for each condition)
(A) and time-lapse microscopy trajectory plots of mSSCs migrating to CXCL12, or 0% or 20% FBS control 20% FBS control (n = 50 cells for each condition) (B),
with similar results observed in three independent experiments.
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Fig. 4. HMGB1 transitions stem cells to GAlert. (A) mSSCs from animals treated locally with exogenous FR- or 3S-HMGB1 dynamically adapted to the known
physiologically rising levels of activating factors with a sustained higher propensity to cycle (n = 4 mice for each condition and time point). (B) Effects of
exogenous FR- or 3S-HMGB1 are mTORC1 dependent in vivo because they are abrogated with rapamycin treatment, as shown by callus volume, callus BMD,
and day 28 mechanical strength (n = 10 mice for each condition). (C) mSSCs, mHSCs, and mMuSCs from the limb contralateral to fracture [fracture (#) alerted]
of Hmgb1−/−mice display ATP levels equivalent to those in quiescent cells from uninjured Hmgb1−/− and Hmgb1fl/fl mice (n = 4 mice for each condition). (D–F)
mSSCs, mHSCs, and mMuSCs from mice treated systemically with FR- or 3S-HMGB1 display increased cellular ATP levels (D), mitochondrial DNA (E) (n = 4 mice
for each condition, separate experiments for each parameter), and cell size (F) (n = 100 cells for each condition, with similar results observed in three in-
dependent experiments from n = 4 mice per condition) compared with vehicle-treated controls and equivalent to that of fracture (#) alerted cells. (G) mSSCs,
mHSCs, and mMuSCs from mice treated systemically with FR- or 3S-HMGB1 display faster entry to cell cycle but more slowly than cells from the limb ipsilateral
to the fracture [fracture (#) activated] cells (n = 4 mice for each condition and time point). *P < 0.05, **P < 0.01, ****P < 0.0001.
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contralateral limb remain in GAlert for 3–4 wk (11), and we found
that 2 wk post FR- or 3S-HMGB1 administration, mSSCs,
mHSCs, and mMuSCs still had elevated ATP (Fig. S6H) even
though circulating levels of HMGB1 had already returned to
baseline (Fig. S6I). Therefore, we investigated whether pre-
treatment with a single i.v. dose of HMGB1 2 wk before injury
would also accelerate bone, hematopoietic, and muscle tissue re-
generation. We observed accelerated tissue regeneration in all
these tissues (Fig. 5 G–M). However, regeneration was observed
only following injury, with no ectopic tissue formation in the 2-wk
period between HMGB1 treatment and injury. This indicates that
HMGB1 treatment is a dynamic and adaptive form of multitissue
A B C
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E F
Fig. 5. HMGB1 accelerates healing of multiple tissues, even if administered 2 wk before injury. (A–C) Systemic administration of FR- or 3S-HMGB1 accelerates
hematopoietic recovery following 5-FU myeloablation (A), as shown by peripheral leukocyte (B) and neutrophil (C) counts (n = 8 mice each for the FR- and 3S-
HMGB1 conditions; n = 9 mice for vehicle-treated controls). (D–F) Local administration of FR- or 3S-HMGB1 accelerates muscle regeneration following BaCl2
injury (D) as shown by increased muscle fiber cross-sectional area (CSA) (E and F) (n = 4 for each condition and time point). (G–M) Systemic administration of
FR- or 3S-HMGB1 2 wk before injury accelerates fracture healing (G) as shown by in vivo microCT radiographs (H), callus volume, callus BMD, and mechanical
strength (I) (n = 10 mice for each condition), hematopoietic recovery (J) as shown by peripheral leukocyte (K) and neutrophil (L) counts (n = 8 mice each for FR-
and 3S-HMGB1 conditions; n = 9 mice for vehicle-treated controls), and muscle regeneration (J) as shown by increased muscle fiber cross-sectional area (CSA)
(M) (n = 5 mice for each condition and time point). *P < 0.05, **P < 0.01, ***P < 0.001.
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regenerative therapy, which takes cues from the steady-state or
tissue-specific activating regenerative molecular signals present at
that time. The preadministration of HMGB1 would be particularly
relevant in situations of planned or expected injury, including
elective surgery, sports medicine, or military combat.
Discussion
We have identified HMGB1 as a therapeutic target that acts on
multiple endogenous adult stem cells to accelerate the physio-
logical regenerative response to current or future injuries. These
findings have broad relevance to the fields of stem cell biology
and regenerative medicine and suggest a therapeutic approach to
promote tissue repair. The existence of the GAlert phase, which is
intermediate between G0 and G1, was described previously (11).
It was noted that stem cells in GAlert enter the cell cycle faster
than those in G0, and initiators of this transition would have
wide-ranging implications for the field of regenerative medicine
by accelerating repair.
We have demonstrated that HMGB1 accelerates the healing
of multiple tissue types by forming a heterocomplex with
CXCL12, which then binds to CXCR4 to transition quiescent
stem cells in three different tissues to GAlert. A recent publica-
tion (20) showed that HMGB1 promotes repair in a murine
model of muscle injury in part by modulating the immune re-
sponse. We utilized prospective multiparameter flow cytometry
isolation methodologies to study the cycling of well-defined en-
dogenous adult stem cell populations in vivo to reduce potential
in vitro artifacts and identified a mechanism of action of FR-
HMGB1 during tissue repair via the initiation of the GAlert state.
Furthermore, we demonstrated that this also pertains to human
stem and progenitor cells.
While our work has focused on endogenous adult stem cells, it
is possible that the transition to GAlert by HMGB1 may also
pertain to other cell types that are usually quiescent in the steady
state, can express CXCR4, and are capable of reentering the cell
cycle to effect tissue repair, such as mature hepatocytes. Indeed,
it was recently observed that HMGB1 treatment results in en-
hanced proliferation of hepatocytes following injury (20). Using
clinically relevant injury models of fracture repair, the response
to chemotherapy, and muscle regeneration in conjunction with
human tissues and cells, we have demonstrated that FR-
HMGB1 leads to accelerated regeneration of multiple tissues by
transitioning the respective stem cells to GAlert.
HMGB1 has critical intracellular and extracellular functions
as demonstrated by the lethality of the constitutive global
knockout (44). In the nucleus HMGB1 interacts with nucleo-
somes, transcription factors, and histones and thus regulates
gene transcription. It has recently been shown that muscle re-
generation is compromised in partial Hmgb1+/− mice (20). We
show here that fracture healing is dramatically impaired in
conditional Hmgb1−/− with robust intracellular and extracellular
protein knockdown and that stem cells fail to transition to GAlert.
We confirmed at the cellular level that exogenous HMGB1 can
rescue the GAlert phenotype but did not evaluate the rescue
at the tissue-healing level as exogenous HMGB1 addition
would not compensate for the critical intranuclear roles of
HMGB1 (44).
While extracellular FR-HMGB1 enhances cell migration by
forming a heterocomplex with the relatively abundant
CXCL12 that is produced following injury, our data show that
the enhanced regenerative effects of the heterocomplex extend
beyond those explained by increased chemotaxis. Indeed, our
finding that systemic pretreatment with HMGB1 2 wk before
injury also accelerates tissue regeneration, with stem cells
remaining in GAlert at this time point (Fig. S6H) despite no ex-
tracellular HMGB1 being detectable systemically to mediate
chemotaxis or other processes (Fig. S6I), suggests that the cel-
lular transition to GAlert is a central mechanism of the
accelerated repair process. This finding also expands the use of
HMGB1 into the contexts of planned or expected potential in-
jury, such as in sports medicine, military combat, and elective
surgery. The last is an area of urgent unmet medical need, as
each person in the United States undergoes on average 9.2 sur-
gical procedures in their lifetime (45).
Fig. 6. Schematic of accelerated tissue regeneration pathway via the dynamic and adaptive HMGB1–CXCL12–CXCR4–GAlert axis. The CXCL12–CXCR4 axis is
known to maintain stem cell quiescence. The highly conserved alarmin, HMGB1, when released following injury or administered in its fully reduced state,
forms a heterocomplex with CXCL12, which then binds to CXCR4, to transition resident stem cells to GAlert. Stem cells remain in this primed state for at least
2 wk, and when they are exposed to activating factors, such as those released following current or future injury, the cells in GAlert enter the cell cycle faster
than cells in G0. This results in accelerated regeneration of multiple tissues.
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HMGB1 is a pleotropic factor, with contrasting effects depending
on the redox status. Our in vitro screen confirmed that only priming
of human bone marrow-derived MSCs by FR- or 3S-HMGB1
promoted osteogenesis on subsequent exposure to osteogenic fac-
tors. We did not find that exogenous administration of FR-HMGB1
either locally or systemically resulted in any untoward inflammation,
suggesting that potential conversion to the proinflammatory disul-
fide form may not be a limitation when considering the develop-
ment of a therapeutic. Furthermore, we did not observe any
significant difference in the regenerative effects of 3S- compared
with FR-HMGB1.
We propose a model (Fig. 6) in which a highly conserved in-
jury signal, HMGB1, acts via a well-established maintenance-
signaling pathway, CXCL12–CXCR4, to ultimately promote
tissue regeneration. Potentially this pathway may be targeted to
accelerate healing in any tissue that relies on repair by cells that
express CXCR4 and can transition to GAlert. In the clinic, we
envisage that FR-HMGB1 would be administered as a single
dose either locally or systemically soon after injury or even up to
2 wk beforehand to accelerate healing.
Materials and Methods
The objective of this study was to understand the role of alarmins in tissue
regeneration in vivo through their effects on adult stem cells and the
translational relevance of these findings. We used human samples and pri-
mary human cells andmultiple murinemodels of injury and regeneration. For
prospective multiparameter flow cytometry assays, we used well-established
skeletal, hematopoietic, and muscle stem cell-surface markers and published
isolation protocols (30, 40, 46). Sample sizes (n values) are reported as bi-
ological replicates of human donors and mice. The data presented were
compiled over the course of 3 y as human samples and mice with the ap-
propriate genotype became available. The magnitude of the effect and vari-
ability in the measurements were used to determine sample size and
replication of data. Although samples were not specifically randomized or
blinded, mouse identification numbers were used when possible as sample
identifiers. Therefore, the genotypes and experimental conditions of each
mouse/sample were not readily known to the experimenters during sample
processing and data collection. Animals were excluded from the study only if
their health status was compromised. In these cases, the animals were handled
in accordance with Home Office guidelines.
All animal procedures were approved by the institutional ethics committee
and the United Kingdom Home Office (PLL 71/7161 and PLL 30/3330). Plasma
samples from human patients who had sustained femoral fractures and from
healthy unfractured controls were obtained from the John Radcliffe Hospital
(Research Ethics Committee Reference: 16/SW/0263, Oxford University Hospital
Research and Development Project Identification Reference: 12229, Integrated
Research Application System Project Identification: 213014).
See SI Materials and Methods for a more detailed description of the
materials and methods used.
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